Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

July 7, 2022

Study Completion Date

November 14, 2022

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

[14C]X842

50 mg/100 µCi \[14C\] X842 suspension

Trial Locations (1)

The First Affiliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors

lead

Jiangsu Sinorda Biomedicine Co., Ltd

INDUSTRY